Newsero
» Protox completes enrollment of Phase 2 BPH trial ...
News
Protox completes enrollment of Phase 2 BPH trial ...
Protox Therapeutics Inc. , a leader in the development of receptor targeted fusion proteins, announced today that it has completed enrollment of patients for its Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia , a common and bothersome urological condition that affects more than 1 million men in Canada and over 50 million men worldwide.
Published in: Procedures and Therapies
Protox Therapeutics Inc. , a leader in the development of receptor targeted fusion proteins, announced today that it has completed enrollment of patients for its Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia , a common and bothersome urological condition that affects more than 1 million men in Canada and over 50 million men worldwide.
Published in: Procedures and Therapies
© 2009 newsero.com 